Journal Article

PreJuSER-45179

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png On the nature of mixed potential in a DMFC

Kulikovsky, A. A.FZJ*

2005
Electrochemical Society Pennington, NJ

This record in other databases:    

Please use a persistent id in citations: http://hdl.handle.net/2128/2878  doi:10.1149/1.1905963

Abstract: This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study.In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated with rufinamide approximately 25-60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests.Overall, patients were treated with rufinamide for a median (range) of 432 (10-1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0% and 47.9% of patients had > or = 50% reduction in total and tonic-atonic seizure frequency, respectively. The most common AEs were vomiting (30.6%) and pyrexia (25.8%).In this open-label extension, rufinamide appeared to be an effective long-term adjunctive therapy for the treatment of LGS-associated seizures in children and young adults.

Keyword(s): J

Note: Record converted from VDB: 12.11.2012

---

Contributing Institute(s):

1. Energieverfahrenstechnik (IWV-3)

Research Program(s):

1. Brennstoffzelle (E01)

Appears in the scientific report 2005
Notes: © The Electrochemical Society, Inc. [year]. All rights reserved. Except as provided under U.S. copyright law, this work may not be reproduced, resold, distributed, or modified without the express permission of The Electrochemical Society (ECS). The archiv

---

Database coverage:

---